Loading
Bluejay Diagnostics, Inc. functions as a company specializing in medical diagnostic solutions. A key offering is their Symphony platform, an advanced technological system. This platform is composed of the Symphony analyzer, which skillfully orchestrates the processing of whole blood, the isolation of biomarkers, and the preparation of immunoassays using non-contact centrifugal force. It also includes the Symphony Cartridge, which comes pre-loaded with essential reagents and components. The company additionally provides the ALLEREYE diagnostic test, a convenient, on-site device for quickly identifying allergic conjunctivitis. Bluejay Diagnostics is also progressing with the development of Symphony IL-6 tests, intended for monitoring disease advancement in critical care environments. Furthermore, they are actively creating additional diagnostic tests for their Symphony platform, such as those aimed at detecting myocardial infarction (heart attack) and congestive heart failure. Bluejay Diagnostics, Inc. was founded in 2015 and is headquartered in Acton, Massachusetts.
NASDAQHealthcareMedical - Devices
Latest quote
$1.01
$0.00 · 0.00%
Latest quote
$1.01
$0.00 · 0.00%
After-hours
$0.9782
−$0.0318 · -3.15%
Sep 10, 7:23 PM ET
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
45
Fair Value
Sentiment
56
Mixed
Risk
67
High Risk
Momentum
19
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Bluejay Diagnostics, Inc. functions as a company specializing in medical diagnostic solutions. A key offering is their Symphony platform, an advanced technological system. This platform is composed of the Symphony analyzer, which skillfully orchestrates the processing of whole blood, the isolation of biomarkers, and the preparation of immunoassays using non-contact centrifugal force. It also includes the Symphony Cartridge, which comes pre-loaded with essential reagents and components. The company additionally provides the ALLEREYE diagnostic test, a convenient, on-site device for quickly identifying allergic conjunctivitis. Bluejay Diagnostics is also progressing with the development of Symphony IL-6 tests, intended for monitoring disease advancement in critical care environments. Furthermore, they are actively creating additional diagnostic tests for their Symphony platform, such as those aimed at detecting myocardial infarction (heart attack) and congestive heart failure. Bluejay Diagnostics, Inc. was founded in 2015 and is headquartered in Acton, Massachusetts.
Day range
Current $1.01
52-week range
Current $1.01
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | 249.04K USD | — |
| Cost of goods sold | — | — | — | 200.13K USD | — |
| Gross profit | — | — | — | 48.91K USD | — |
| Research and development | 3.05M USD | 3.47M USD | 5.71M USD | 4.15M USD | 1.15M USD |
| Selling, general, and administrative | 3.91M USD | 3.7M USD | 4.6M USD | 5.21M USD | 2.08M USD |
| Operating expenses | 6.95M USD | 7.17M USD | 10.31M USD | 9.37M USD | 3.23M USD |
| Interest income | 97.56K USD | 145.82K USD | 164.9K USD | 89.67K USD | 513.3K USD |
| Interest expense | 839 USD | 823.03K USD | — | — | 367.46K USD |
| Depreciation and amortization | 170.68K USD | 199.1K USD | 780.96K USD | 306.37K USD | 145.72K USD |
| Operating income | −6.95M USD | −7.17M USD | −10.31M USD | −9.32M USD | −3.23M USD |
| Net income | −6.85M USD | −7.72M USD | −9.95M USD | −9.3M USD | −3.73M USD |
Company facts updated Sep 10, 2026.
Recent quarterly results
Recent quarterly results
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jan 29, 2026 | 1:4 | — | — |
Stock split | Nov 18, 2024 | 1:50 | — | — |
Stock split | Jun 20, 2024 | 1:8 | — | — |
Stock split | Jul 24, 2023 | 1:20 | — | — |
Effective Jan 29, 2026
1:4
Effective Nov 18, 2024
1:50
Effective Jun 20, 2024
1:8
Effective Jul 24, 2023
1:20
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
